As Pharma Looks Beyond The Molecule For Innovation, Can VCs Take Advantage?
This article was originally published in Start Up
Executive Summary
Big Pharma’s growing interest in innovation beyond the molecule that improves health outcomes could provide new opportunities for biotechs and their venture capital backers, but in many areas investors have approached cautiously.